Efficacy and Safety of Pomalidomide in Combination With Low-dose Dexamethasone in Chinese Patients With Relapsed and Refractory Multiple Myeloma

Phase 3 Unknown 73 enrolled Jiangsu Simcere Pharmaceutical Co., Ltd.

NaSingle-groupOpen-labelTreatment

Summary

This study aims to assess the efficacy and safety of pomalidomide in combination with low-dose dexamethasone in Chinese patients with relapsed and refractory multiple myeloma.

Timeline

Start: 2016-09
Primary completion: 2018-06
Completion: 2019-06

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Pomalidomide	Other / unclassified	4 mg	—
Background	Dexamethasone	Small molecule	20 mg	—
Background	Dexamethasone	Small molecule	40 mg	—

Efficacy and Safety of Pomalidomide in Combination With Low-dose Dexamethasone in Chinese Patients With Relapsed and Refractory Multiple Myeloma

Summary

Timeline

Drugs

Indications